The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine
Open accessAbstract
Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease (1). Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Sixteen cases of meningococcal disease were identified in eculizumab recipients in the United States during 2008-2016; among these, 11 were caused by nongroupable Neisseria meningitidis. Fourteen patients had documentation of receipt of at least 1 dose of meningococcal vaccine before disease onset. Because eculizumab recipients remain at risk for meningococcal disease even after receipt of meningococcal vaccines, some health care providers in the United States as well as public health agencies in other countries recommend antimicrobial prophylaxis for the duration of eculizumab treatment; a lifelong course of treatment is expected for many patients. Heightened awareness, early care seeking, and rapid treatment of any symptoms consistent with meningococcal disease are essential for all patients receiving eculizumab treatment, regardless of meningococcal vaccination or antimicrobial prophylaxis status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lessons from meningococcal carriage studies
Caugant, D. A., Tzanakaki, G., & Kriz, P. (2007) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2006.00052.x · Cited by 193
Konar, M., & Granoff, D. M. (2017) · Blood · doi:10.1182/blood-2017-05-781450 · Cited by 132
Harcourt, B. H., Anderson, R. D., Wu, H. M., Cohn, A. C., MacNeil, J. R., Taylor, T. H., Wang, X., Clark, T. A., Messonnier, N. E., & Mayer, L. W. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv117 · Cited by 60
Self-citationKretz, C. B., Retchless, A. C., Sidikou, F., Issaka, B. B., Ousmane, S., Schwartz, S., Tate, A. H., Panà, A., Njanpop‐Lafourcade, B., Nzeyimana, I., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2210.160468 · Cited by 60
Self-citation
Cited by
Lee, J. W., Sicre de Fontbrune, F., Wong Lee Lee, L., Pessoa, V., Gualandro, S., Füreder, W., Ptushkin, V., Rottinghaus, S. T., Volles, L., Shafner, L., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876136 · Cited by 416
Kulasekararaj, A. G., Hill, A., Rottinghaus, S. T., Langemeijer, S., Wells, R., Gonzalez-Fernandez, F. A., Gaya, A., Lee, J. W., Gutierrez, E. O., Piatek, C. I., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876805 · Cited by 382
The renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Carnero Contentti, E., & Correale, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 338
Mbaeyi, S. A., Bozio, C. H., Duffy, J., Rubin, L. G., Hariri, S., Stephens, D. S., & MacNeil, J. R. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6909a1 · Cited by 321
Self-citation
Metadata
- Authors
- McNamara, L. A., Topaz, N., Wang, X., Hariri, S., Fox, L., & MacNeil, J. R.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2017-07-14
- Volume
- 66
- Issue
- 27
- Pages
- 734-737
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W2730107276
- Cited by
- 349
- References
- 4
- FWCI
- 22.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. https://app.cochat.ai/papers/10.15585/mmwr.mm6627e1
- The paper
- McNamara, L. A., Topaz, N., Wang, X., Hariri, S., Fox, L., & MacNeil, J. R. (2017). High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6627e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.